To upgrade its current facility for producing biologicals, biosimilars, antibodies, and recombinant insulin, Gland Pharma announced an investment of more than Rs. 400 crore at Genome Valley. The expanded facility will help more than 500 qualified, skilled, and semi-skilled workers find jobs. After a $300 billion investment, the corporation opened a biopharmaceutical plant in Genome Valley in February 2022 to produce vaccines, biologicals, biosimilars, antibodies, and other products. The facility has hired more than 200 people. The Rs. 400 crore investment announcement was made after Industries Minister KT Rama Rao’s meeting with Gland Pharma Managing Director and Chief Executive Officer Srinivas Sadu.